Lung Cancer Online
Home Care Support Info Treatment Effects Tests Surviving Sites MedLit

 home > treatment > agents & regimens > huN901

huN901-DM10901 : ImmunoGen & British Biotch : monoclonal antibody

Second Phase I Study of huN901-DM1/BB-10901 (British Biotech)
Announcement of a second Phase 1 study of huN901-DM1/BB-10901, a novel anti-cancer agent targeted at SCLC that uses a humanized monoclonal antibody to deliver a highly potent chemotherapeutic agent specifically to the site of the tumor. [8/02]


 

Feedback / Queries Disclaimer Advocacy - You Can Help

Copyright © 1999-2006, Lung Cancer Online Foundation
Last modified: 18-Feb-2009
Karen Parles, MLS Editor